Innospera Pharma, a biotech company headquartered in Montreal, announced the appointment of François Ravenelle as its new president and chief executive officer. Ravenelle, formerly of Inversago Pharma, brings over two decades of experience in pharmaceutical research and development and executive management to Innospera.
Nearing the clinical stage, Innospera is developing small molecule modulators for receptors involved in various chronic and fibrotic conditions. Its lead drug candidates work to combat inflammatory and metabolic diseases caused by aging.
“With strong preclinical evidence and the potential to address chronic conditions such as idiopathic pulmonary fibrosis, Innospera is uniquely positioned to make a meaningful impact in the field of inflammatory-related conditions,” Ravenelle said in a statement. “I’m excited to contribute to the company’s next phase of growth.”
